AVEO Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on AVEO Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date AVEO Pharmaceuticals Inc Strategy Report
- Understand AVEO Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
AVEO Pharmaceuticals Inc (AVEO), is a biopharmaceutical company that focuses on the discovery, development, and commercialization of drugs for the treatment of various types of cancers. Its flagship product tivozanib is approved as a first line treatment for adult patients with renal cell carcinoma and marketed under the brand name Fotivda in European Union, Iceland and Norway. The company’s clinical product includes Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, and AV-203, an anti-ErbB3 monoclonal antibody. It also has pre-clinical products in the pipeline. The company develops products through strategic partnerships with other pharmaceutical companies. AVEO is headquartered in Boston, Massachusetts, the US.
Headquarters
United States of America
Address
30 Winter Street, Boston, Massachusetts, 02108
Website
www.aveooncology.com
Telephone
1 857 4000101
Industry
Pharmaceuticals and Healthcare
AVEO Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Tivozanib- Tyrosine Kinase Inhibitor |
| Ficlatuzumab- Hepatocyte Growth Factor Inhibitory Antibody |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Ownership Changes | In March, the company was acquired by LG Chem for US$571 million. |
| 2022 | Contracts/Agreements | In March, the company and Actinium Pharmaceuticals signed an agreement to develop and study a first-in-class antibody radio-conjugate targeting ErbB3, which is also known as HER3. |
| 2022 | Contracts/Agreements | In January, the company entered into a clinical trial collaboration and supply agreement with Merck KGaA to evaluate ficlatuzumab in combination with ERBITUX (cetuximab) in patients with recurrent or metastatic head and neck squamous cell carcinoma. |
Competitor Comparison
| Key Parameters | AVEO Pharmaceuticals Inc | Mirati Therapeutics Inc | Galaxy Biotech LLC | IFM Therapeutics LLC | Merrimack Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Boston | San Diego | Sunnyvale | Boston | Cambridge |
| State/Province | Massachusetts | California | California | Massachusetts | Massachusetts |
| No. of Employees | - | 587 | - | - | - |
| Entity Type | Private | Private | Private | Private | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Kenneth M. Bate | Chairman | Executive Board | 2021 | - |
| Jinchul Jeong | Chief Financial Officer | Senior Management | - | - |
| Jebediah Ledell | Chief Operating Officer | Senior Management | 2021 | - |
| Edgar E. Braendle, MD, Ph.D | Chief Medical Officer | Senior Management | 2024 | - |
| Mike Ferraresso | Chief Commercial Officer | Senior Management | 2017 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward